Radionuclide-labelled nanoparticles for cancer combination therapy: a review

Abstract

Abstract Radionuclide therapy (RT) is widely used to advanced local cancers. However, its therapeutic efficacy is limited to the radiation resistance of cancer cells. Combination therapy aims to circumvent tumor resistance, and the combination of RT with photothermal therapy (PTT), photodynamic therapy (PDT), chemotherapy (CMT), and immunotherapy has shown promising treatment outcomes. Nanotechnology holds promise in advancing combination therapy by integrating multiple therapies on a nanostructure platform. This is due to the increased surface area, passive/active targeting capabilities, high payload capacity, and enriched surface of nanomedicines, offering significant advantages in treatment sensitivity and specificity. In the first part of this review, we categorize radionuclide therapy. The second part summarizes the latest developments in combination therapies, specifically focusing on the integration of RT with PTT, PDT, CMT and immunotherapy. The last part provides an overview of the challenges and potential opportunities related to radionuclide-labelled nanoparticles for cancer combination therapy. Graphical Abstract

Keywords

• Radionuclides
• Nanoparticles
• Combination therapy